A federal ruling invalidating human gene patents by Myriad Genetics (MYGN -5.4%) may have...


A federal ruling invalidating human gene patents by Myriad Genetics (MYGN -5.4%) may have far-reaching effects; if upheld, it could shake multibillion-dollar industries built on the intellectual property rights granted by the patents taken out on 20% of human genes.

From other sites
Comments (1)
  • bearishondisco
    , contributor
    Comments (50) | Send Message
     
    Freedom scores a touchdown against tyranny; but it's still the first quarter.
    30 Mar 2010, 12:25 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs